Alx Oncology Holdings (ALXO) Operating Expenses (2019 - 2026)

For the trailing twelve months through Jun 30, 2026, Operating Expenses at Alx Oncology Holdings was $82.55 million, down 32.1% year-over-year; for FY2025, it was $104.02 million, down 27.0% from FY2024.

• Annual Operating Expenses shows a five-year compound annual growth rate of 18.3% (FY2020 to FY2025).
• In prior years, Alx Oncology Holdings' Operating Expenses was $142.47 million in FY2024 (-16.3%), $170.28 million in FY2023 (+33.6%), $127.44 million in FY2022 (+52.5%) and $83.56 million in FY2021 (+86.3%).
• The Q2 2026 figure stands as the lowest quarterly Operating Expenses since Q2 2021.
• On a year-over-year basis, Operating Expenses has declined in each of the last eight quarters, with an average decline of 31.9% over the last eight quarters.
• The strongest year-over-year quarter for Operating Expenses in the past five years was Q3 2021, with growth of 150.5%; the weakest was Q1 2026, with a decline of 40.4%.
• According to Business Quant data, Operating Expenses for the three prior quarters was $18.97 million (Q1 2026), $23.02 million (Q4 2025) and $22.53 million (Q3 2025).